

Disclaimer	
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.	
Cash Dividend Announcement for Equity Issuer	
Issuer name	DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
Stock code	02348
Multi-counter stock code and currency	Not applicable
Other related stock code(s) and name(s)	Not applicable
Title of announcement	FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2022 AND CLOSURE OF REGISTER OF MEMBERS
Announcement date	24 March 2023
Status	New announcement
Information relating to the dividend	
Dividend type	Final
Dividend nature	Ordinary
For the financial year end	31 December 2022
Reporting period end for the dividend declared	Not applicable
Dividend declared	HKD 0.073 per share
Date of shareholders' approval	25 May 2023
Information relating to Hong Kong share register	
Default currency and amount in which the dividend will be paid	HKD 0.073 per share
Exchange rate	HKD 1 : HKD 1
Ex-dividend date	30 May 2023
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	31 May 2023 16:30
Book close period	From 01 June 2023 to 02 June 2023
Record date	02 June 2023
Payment date	13 June 2023
Share registrar and its address	TRICOR ABACUS LIMITED
	17/F, Far East Finance Centre
	16 Harcourt Road, Hong Kong. Hong Kong
Information relating to withholding tax	
Details of withholding tax applied to the dividend declared	Not applicable

Information relating to listed warrants / convertible securities issued by the issuer	
Details of listed warrants / convertible securities issued by the issuer	Not applicable
Other information	
Other information	Not applicable
Directors of the issuer	
As at the date of this announcement, the Board of the Company comprises two executive directors, namely Ms. Li Kei Ling and Mr. Hung Yung Lai; one non-executive director, Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.	